CAN 001
Alternative Names: CAN-001 - Ethicann PharmaceuticalsLatest Information Update: 28 May 2023
At a glance
- Originator Ethicann Pharmaceuticals
- Class Antiemetics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Chemotherapy-induced-nausea-and-vomiting in Canada
- 02 Apr 2019 Preclinical trials in Chemotherapy-induced nausea and vomiting in Canada (unspecified route)
- 02 Apr 2019 Ethicann Pharmaceuticals anticipates to submit regulatory application with the US FDA to seek marketing approval for CAN 001 for Chemotherapy-induced nausea and vomiting in early 2020